Technology

Study: Gut Microbiome Data May Be Useful in Screening for Heart Disease

September 10, 2020

The study investigators used artificial intelligence to analyze gut microbiome data in individuals with and without cardiovascular disease.

The Rise of AI

September 09, 2020

An examination of how this innovation is affecting pharmacy.

FDA OKs Hybrid Closed Loop Diabetes Management Device for Use in Young Children

September 01, 2020

The MiniMed 770G system (Medtronic) is approved for use by individuals aged 2 to 6 with type 1 diabetes.

FDA Issues Emergency Use Authorization to New 15-Minute COVID-19 Antigen Test

August 27, 2020

Abbott’s BinaxNOW COVID-19 Ag Card rapid test produces results in 15 minutes.

Telehealth Improves Access to Pharmacists for Medically Underserved Patients

August 24, 2020

An examination of how telehealth services for medically underserved patients in rural areas improve access to pharmacists for chronic care management.

Maximizing Adherence Packaging for Patient Health and Pharmacy Growth

August 17, 2020

Is adherence packaging technology a big investment for a community or independent pharmacy?

Protect Your Pharmacy’s Online Presence

August 13, 2020

Focus on best practices and implement new technology to safeguard against security breaches.

Why Patient Education Is More Important Than Ever

August 12, 2020

How pharmacists can address knowledge gaps and health literacy challenges to help people with chronic conditions stay adherent to drug therapies

Stay in Sync with Innovations in Medication Decision Support

August 06, 2020

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

Youth Involvement in Decision to Start CGM Linked to Consistent Use

August 04, 2020

Youth with diabetes who are involved in the decision to start continuous glucose monitoring reported consistent use 2 months after starting.

Coronavirus News Roundup: FDA Fast Tracks 2 Vaccines, NCPA Launches Relief Package Campaign

July 17, 2020

Here's the coronavirus-related news you should know from this week.

Episode 5: COVID-19 Innovations are Here to Stay

July 16, 2020

In episode 5 of Over the Counter, experts in technology and pharmacy highlight the major ways that telemedicine is rising to meet the COVID-19 pandemic.

Computer Model Helps Researcher Predict Regional Disease Burden

July 16, 2020

A new computer model can help researchers predict the regional areas where vaccines are needed most.

Coronavirus News Roundup: FDA Authorizes New Diagnostic Test, Advancements in AI Tools

July 10, 2020

Here's the coronavirus-related news you should know from this week.

Part 2: Innovations in AI Amid COVID-19

July 07, 2020

Drug Topics interviews Steve Mok, PharmD, manager of pharmacy services and director of health outcomes and analytics fellowship at Wolters Kluwer, to break down the ways that artificial intelligence can mitigate challenges posed by the COVID-19 pandemic.

FDA Authorizes Third Combination Diagnostic Test for Flu and COVID-19

July 06, 2020

The FDA has granted emergency use authorization to an additional combination diagnostic test for influenza and COVID-19.

AI Innovations Amid COVID-19

July 03, 2020

Drug Topics interviews Steve Mok, PharmD, BCPS, BCIDP, manager of pharmacy services and director of health outcomes and analytics fellowship at Wolters Kluwer, to break down the ways that artificial intelligence (AI) can mitigate challenges posed by the COVID-19 pandemic.

NACDS: Electronic Prescriptions for Controlled Substances Should be Mandatory

July 02, 2020

NACDS is urging the Drug Enforcement Administration to make electronic prescriptions for controlled substances mandatory.

New Machine Learning Tool Can Predict Adverse Drug Effects

June 29, 2020

A new computer algorithm might be the next step toward accurate prediction of adverse drug reactions.

FDA Clears First Prescription Game-Based Treatment Device for Children With ADHD

June 17, 2020

EndeavorRx (Akili Interactive), a prescription-only game-based device, is indicated for use in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue.